• Locations
  • Conditions
  • Treatments
  • Institutions
  • Resources
  • For researchers
  • About us
Facebook link logoLinkedin link logo
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
LocationsTexasArizonaCaliforniaNew YorkMassachusettsFloridaNew JerseyUtahAll locationsConditionsOncologyAlzheimer'sDiabetesMultiple SclerosisArthritisHepatitis CCOPDDepressionAll conditionsTreatmentsWeight LossStem CellsVaccinesSleep ApneaMedical DevicesIVFDentalDrug AddictionAll treatmentsInstitutionsPfizerModernaNIHUCLAStanfordM.D. AndersonLabcorpAll institutionsResourcesBlogFAQMedical advisors
Terms of usePrivacy policy
All Clinical Trials 2026All Rights reservedPrivacy PolicyTerms of Use
  1. Clinical trials
  2. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
  3. Apply

Gedatolisib, Fulvestrant, CDK4/6 InhibitorsPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Basic information
Step 1/5

Provide your basic information